MOB — Moberg Pharma AB (publ) Share Price
0.000.00%
Last trade - 00:00- SEK378.45m
- SEK89.30m
- SEK9.81m
- 46
- 21
- 37
- 23
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.55 | ||
| Price to Tang. Book | 0.99 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 38.57 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -47.12% | ||
| Return on Equity | -39.32% | ||
| Operating Margin | -3310.88% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | SEKm | 50.49 | n/a | 0.21 | n/a | 9.81 | 17 | 65 | -8.8% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Moberg Pharma AB (publ), formerly Moberg Derma AB (publ) is a Sweden-based pharmaceutical company. The Company is a pharmaceutical company in dermatology focused on the commercialization of proprietary drugs based on proven substances. Moberg Pharma AB (publ) develops MOB-015, the treatment of nail fungus. Its product portfolio includes products for the treatment of skin diseases, pain, the treatment of nails damaged by fungus or psoriasis, dry and damaged feet and range of products for several types of skin and scalp problems. The Company deals with development, manufacture, direct and indirect sale, marketing and licensing of pharmaceuticals, medical devices and skin care products as well as related activities.
Directors
- Peter Wolpert CHM (51)
- Anna Ljung CEO (42)
- Mark Beveridge VFN (42)
- Agneta Larhed VPR
- Annica Magnusson OTH (57)
- Cindy Wong OTH (61)
- Fredrik Granstrom IND (52)
- Andrew Hochman IND (42)
- Mattias Klintemar IND (54)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- January 31st, 2006
- Public Since
- May 26th, 2011
- No. of Employees
- 9
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- OMX Nordic Exchange Stockholm
- Shares in Issue
- 46,693,332
- Address
- Gustavslundsvagen 42, 5 tr., BROMMA, 167 51
- Web
- https://www.mobergpharma.se/
- Phone
- +46 852230700
- Auditors
- Ernst & Young AB
Upcoming Events for MOB
Moberg Pharma AB (publ) Annual Shareholders Meeting
Moberg Pharma AB (publ) Annual Shareholders Meeting
Q2 2025 Moberg Pharma AB (publ) Earnings Release
Similar to MOB
Biogaia AB
OMX Nordic Exchange Stockholm
BoneSupport Holding AB
OMX Nordic Exchange Stockholm
Camurus AB
OMX Nordic Exchange Stockholm
Cinclus Pharma Holding publ AB
OMX Nordic Exchange Stockholm
Corline Biomedical AB
OMX Nordic Exchange Stockholm
FAQ
What is the Moberg Pharma AB (publ) share price?
As of Today at 22:05 UTC, shares in Moberg Pharma AB (publ) are trading at SEK8.11. This share price information is delayed by 15 minutes.
How has the Moberg Pharma AB (publ) share price performed this year?
Shares in Moberg Pharma AB (publ) last closed at SEK8.11 and the price had moved by -76.26% over the past 365 days. In terms of relative price strength the Moberg Pharma AB (publ) share price has underperformed the FTSE Global All Cap Index by -76.85% over the past year.
What are the analyst and broker recommendations for Moberg Pharma AB (publ)?
The overall consensus recommendation for Moberg Pharma AB (publ) is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Moberg Pharma AB (publ) dividend yield?
Moberg Pharma AB (publ) does not currently pay a dividend.
Does Moberg Pharma AB (publ) pay a dividend?
Moberg Pharma AB (publ) does not currently pay a dividend.
When does Moberg Pharma AB (publ) next pay dividends?
Moberg Pharma AB (publ) does not currently pay a dividend.
How do I buy Moberg Pharma AB (publ) shares?
To buy shares in Moberg Pharma AB (publ) you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Moberg Pharma AB (publ)?
As of the previous close price of SEK8.11, shares in Moberg Pharma AB (publ) had a market capitalisation of SEK378.45m.
Where are Moberg Pharma AB (publ) shares listed?
Here are the trading details for Moberg Pharma AB (publ):
- Country of listing: Sweden
- Exchange: STO
- Ticker Symbol: MOB
What kind of share is Moberg Pharma AB (publ)?
Based on an overall assessment of its quality, value and momentum Moberg Pharma AB (publ) is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Moberg Pharma AB (publ) share price forecast for 2025?
The analyst consensus target price for shares in Moberg Pharma AB (publ) is SEK11.00. That is 35.72% above the last closing price of SEK8.11.
Analysts covering Moberg Pharma AB (publ) currently have a consensus Earnings Per Share (EPS) forecast of -SEK0.50 for the next financial year.
Find out moreWhat is the trend in the Moberg Pharma AB (publ) share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Moberg Pharma AB (publ). Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -30.82%.
As of the last closing price of SEK8.11, shares in Moberg Pharma AB (publ) were trading -49.55% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Moberg Pharma AB (publ) PE Ratio?
The Moberg Pharma AB (publ) PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at SEK8.11.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Moberg Pharma AB (publ)?
Moberg Pharma AB (publ)'s management team is headed by:
- Peter Wolpert - CHM
- Anna Ljung - CEO
- Mark Beveridge - VFN
- Agneta Larhed - VPR
- Annica Magnusson - OTH
- Cindy Wong - OTH
- Fredrik Granstrom - IND
- Andrew Hochman - IND
- Mattias Klintemar - IND